We are live on ! Find out more
TRIB

Trinity Biotech

27 hedge funds and large institutions have $673K invested in Trinity Biotech in 2025 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 3

119% more call options, than puts

Call options by funds: $57K | Put options by funds: $26K

4% less funds holding

Funds holding: 2827 (-1)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

76% less capital invested

Capital invested by funds: $2.81M → $673K (-$2.13M)

82.03% less ownership

Funds ownership: 119.67%37.64% (-82%)

Holders
27
Holders Change
-1
Holders Change %
-3.57%
% of All Funds
0.33%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
9
Reduced
3
Closed
7
Calls
$57K
Puts
$26K
Net Calls
+$31K
Net Calls Change
-$6K

TRIB Hedge Fund Activity: Q4 2025 in Review

27 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q4 2025, worth a combined $673K — down 76% from $2.81M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of TRIB and 6 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 9 added.

The largest buyer was Williams & Novak, adding an estimated $79.9K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $1.86M sold.

  • 27 institutional investors held Trinity Biotech (TRIB) as of Q4 2025, down from 28 in Q3 2025.
  • Funds reported $673K of Trinity Biotech stock for Q4 2025, down 76% quarter-over-quarter.
  • 6 funds opened new Trinity Biotech positions in Q4 2025 and 7 closed out, a net change of -1 holder.
  • The largest Trinity Biotech buyer in Q4 2025 was Williams & Novak, an estimated $79.9K added.
  • The largest Trinity Biotech seller in Q4 2025 was Perceptive Advisors, an estimated $1.86M sold.

Based on aggregated 13F filings for Q4 2025.